Semaglutide denied as not medically necessary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for semaglutide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Semaglutide on Medical-Necessity Grounds

UHC's medical-necessity denials for semaglutide reflect a conclusion at initial review that the submitted clinical documentation did not satisfy one or more criteria in UHC's coverage determination guidelines for this drug class. These criteria typically address the underlying diagnosis, prior-treatment history, and current clinical status. Initial medical-necessity denials are frequently reversed on appeal because the supporting documentation exists in the patient's chart but was not attached to the original authorization request.

## Why This Denial Is Appealable

A medical-necessity denial is a reviewable coverage determination, not a final clinical judgment. Under ACA Section 2719 and ERISA Section 503, every member has the right to a full-and-fair internal appeal followed by independent external review by a reviewer with no relationship to the plan. For urgent clinical situations, an expedited review — typically resolved within 72 hours — is also available. The window for requesting external review is generally open for approximately four months from the date of the adverse determination.

## The Appeal Process

1. Request the complete denial rationale — UHC must provide the specific criteria it found unmet and cite the clinical guideline or coverage policy used. 2. File the internal appeal — confirm the filing deadline from your Explanation of Benefits (commonly 180 days from the denial date). 3. Request a peer-to-peer review — UHC allows treating physicians to speak directly with the reviewing clinician, and this conversation resolves many denials before a formal appeal is needed. 4. Escalate to independent external review if the internal appeal is denied.

## Documentation to Gather

• Diagnosis confirmation: clinical notes, relevant lab work, imaging, or assessment scores from the medical record establishing the qualifying diagnosis.
• Prior-treatment history: a chronological list of previously tried therapies — drug name, start date, end date, and documented outcome — demonstrating that prior steps have been completed.
• Clinical severity and functional impact: objective chart findings showing the current severity of the condition and its impact on the patient's health or function.
• Prescriber medical-necessity letter: a detailed letter addressing each criterion in UHC's coverage policy, written specifically for this patient and this denial rather than a generic template.

## Criteria-Mapping Structure

Obtain UHC's current Coverage Determination Guideline for semaglutide and the FDA-approved prescribing label. List each coverage criterion. For each one, identify the specific chart entry — provider name, date, finding — that satisfies it. A structured table submitted alongside the prescriber's letter is significantly more persuasive than narrative alone and gives the appeal reviewer a clear path to approving coverage.